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Good Publication Practice (GPP) is a set of guidelines 
within the health care communication industry that 
encourages the responsible and ethical publication 
of scientific data. GPP has its origins in the mid-
1990s when it first came to public awareness that 
involvement of unacknowledged, industry-funded 
medical writers could compromise the integrity of 
scientific articles. While medical writers were initially 
regarded skeptically by medical journal editors, their 
valuable contribution to the accuracy and currency of 
scientific communications is now fully acknowledged 
and a more balanced view of the relationship between 
author, sponsor and medical writer is gradually 
emerging. In fact, a 2007 article in the British Medical 
Journal commented that: “medical writers are not 
a fifth column but are working in a fast-moving 
modern environment to help disseminate scientific 
information…. and their work needs to be embraced 
and acknowledged…”.1 Furthermore, the World 
Association of Medical Editors (WAME) urges editors 
to make it clear in their instructions to authors that 
medical writers can be legitimate contributors.2 
However, a recent editorial in the Financial Times 
makes it clear that, “Using professional writers to 
improve the standard of manuscripts submitted to 
medical journals is acceptable, and even desirable. 
Ghost-writing, which conceals the underlying influence 
and authorship, is wrong.”3  Since it is in the interest of 
all parties involved in disseminating scientific data to 
eliminate such questionable practices, various national 
and international guidelines have been developed to 
ensure that manuscripts are not only of a high quality, 
but that the preparation process is beyond reproach.
The Good Publication Practice for the Pharmaceutical 
Companies4 (GPPPC) guidelines were first published in 
2003 and updated in 2009. These guidelines are aimed 
to increase transparency and to encourage the ethical 
dissemination of data. Numerous guidelines produced 
by associations representing medical writers, medical 
editors and the pharmaceutical industry have followed 
and continue to evolve.
Authorship is key to the integrity of any written 
communication, and the definition of an author given 
by the International Committee of Medical Journal 
Editors5(ICMJE) is widely accepted. According to 
this definition, an author must make a substantial 
contribution to the conception and design, acquisition 
of data or analysis and interpretation of data, as well 
as writing the first draft of the article (or revising 
it critically) and giving final approval. The ICMJE 
also stipulates that all authors must take public 
responsibility for their work. If authors do use the 
services of medical writers, they must always agree 
with the content and outline with the writer before the 
first draft is written and the two parties must maintain 
contact throughout development of the manuscript.4
Given the ICMJE criteria, it is clear that medical writers 
will not usually qualify to be authors, perhaps with 
the exception of review articles in which the writer 
performed the literature search, identified articles 
and evaluated the data. However, there is universal 
agreement that a medical writer’s contribution should 
be clearly acknowledged in the article and any funding 
disclosed.2, 4, 6 WAME goes further and considers 
all parties involved in concealing medical writer 
involvement to be responsible (including marketing, 
communications and medical education companies) 
and suggests the ‘naming and shaming’ of culprits.7 
Of course, the scope of GPP guidelines goes beyond 
the single issue of medical writers and covers other 
areas crucial to the unbiased communication of 
biomedical literature. The ICMJE and the GPPPC 
discourage duplicate publications of data. Exceptions 
include symposium proceedings, alternative analyses, 
data grouping with other studies and publication for 
different audiences.4,5 Furthermore, WAME requires 
that authors disclose details of related papers they 
have authored, even if they are in a different language, 
in press or submitted to another journal.3 The ICMJE 
and the GPPPC consortium are also among the 
organizations seeking to persuade pharmaceutical 
companies to publish all trial results, negative as well 
as positive.4,5 To this end, the ICMJE, the GPPPC and 
WAME strongly support the registration of clinical 
methodology,4,5,7 while the 2007 FDA Amendment Act 
goes a step further and requires that researchers also 
register all trial results. This policy should go a long way 
to identifying unpublished–and therefore probably 
negative–data which will help to avoid a potentially 
misleading weighting of results. 
Conflict of interest disclosure is another area taken 
very seriously by medical journal editors; the Journal 
of the American Medical Association investigates all 
allegations of undisclosed conflicts, emphasizing that 
reporting the best available biomedical science is of 
prime importance and should not be jeopardized by 
such misrepresentation.8
GPP guidelines are continuing to develop and are 
gaining wide acceptance by all parties involved in the 
communication and dissemination of biomedical 
information. The principles of clear, unbiased and 
ethical reporting of results, opinions and ideas can only 
be of benefit to the medical community in particular 
and society as a whole. 
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